CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 31, Issue 6, Pages 593-605
Publisher
Informa UK Limited
Online
2022-03-21
DOI
10.1080/13543784.2022.2054326
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-risk triple-negative breast cancers: clinico-pathological and molecular features
- (2022) Nicola Fusco et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapy for early triple negative breast cancer: research agenda for the next decade
- (2022) Paolo Tarantino et al. npj Breast Cancer
- Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
- (2021) Maria Vittoria Dieci et al. Cells
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
- (2021) Ruimin Hong et al. Frontiers in Immunology
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2021) Nicola Fusco et al. Frontiers in Oncology
- Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls
- (2021) G. Antonarelli et al. ANNALS OF ONCOLOGY
- Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology
- (2021) Carmen Criscitiello et al. Anti-Cancer Agents in Medicinal Chemistry
- Managing side effects of immune checkpoint inhibitors in breast cancer
- (2021) Carmen Criscitiello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- MUC1: Structure, Function, and Clinic Application in Epithelial Cancers
- (2021) Wenqing Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.
- (2021) Rodolfo Gutierrez et al. JOURNAL OF CLINICAL ONCOLOGY
- OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
- (2021) Andrew Tutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- (2021) Chiara Corti et al. Cancers
- Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
- (2021) K.S. Saini et al. ANNALS OF ONCOLOGY
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Therapeutic vaccines for breast cancer: Has the time finally come?
- (2021) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
- (2021) Paolo Tarantino et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novel immune targets for the treatment of triple-negative breast cancer
- (2021) Chiara Corti et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
- (2021) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
- (2021) Sara Bravaccini et al. Journal of Personalized Medicine
- Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
- (2020) Guoxuan Gao et al. BMC CANCER
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
- (2020) Rebecca C. Abbott et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
- (2020) Zhiwei Hu Scientific Reports
- CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
- (2020) Simona Porcellini et al. Frontiers in Immunology
- Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options
- (2020) Giulia Grizzi et al. Cancer Management and Research
- Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
- (2020) Sima Lev BIOCHEMICAL SOCIETY TRANSACTIONS
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Exploiting the folate receptor α in oncology
- (2020) Mariana Scaranti et al. Nature Reviews Clinical Oncology
- Cancer cell therapies: the clinical trial landscape
- (2020) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
- (2020) C. Criscitiello et al. BREAST CANCER RESEARCH AND TREATMENT
- CAR T-cell therapy for triple-negative breast cancer: Where we are
- (2020) Yuetao Xie et al. CANCER LETTERS
- Cellular immunotherapy in breast cancer: the quest for aconsistent biomarkers
- (2020) Konstantinos Venetis et al. CANCER TREATMENT REVIEWS
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
- (2020) Bassel Nazha et al. Frontiers in Oncology
- Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer
- (2020) Sundee Dees et al. MOLECULAR CANCER THERAPEUTICS
- Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
- (2020) Heng Wei et al. Frontiers in Immunology
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
- (2020) Niels Schaft Cancers
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- CD44 as a tumor biomarker and therapeutic target
- (2020) Hanxiao Xu et al. Experimental Hematology & Oncology
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
- (2019) Luca Cassetta et al. CANCER CELL
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Current Landscape of Immunotherapy in Breast Cancer
- (2019) Sylvia Adams et al. JAMA Oncology
- CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
- (2019) Lynsey M. Whilding et al. Cancers
- Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
- (2019) Sandhya R. Panch et al. MOLECULAR THERAPY
- Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
- (2019) Max D. Wellenstein et al. NATURE
- CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
- (2019) Ru Zhou et al. Frontiers in Immunology
- An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment
- (2019) Yi Wang et al. Frontiers in Immunology
- Preservation of cell-based immunotherapies for clinical trials
- (2019) RUI LI et al. CYTOTHERAPY
- In vitro elimination of EGFR‐overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab
- (2019) Sara Caratelli et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
- (2019) Manuel Wiesinger et al. Cancers
- Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
- (2019) Fabio Pagni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
- (2019) Dennis C. Harrer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach
- (2019) Yacine Bareche et al. JNCI-Journal of the National Cancer Institute
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions
- (2019) Stephen J. Bagley et al. PHARMACOLOGY & THERAPEUTICS
- TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
- (2019) Kristina Petrovic et al. PLoS One
- GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
- (2019) Christian M. Seitz et al. OncoImmunology
- EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
- (2019) Yan Liu et al. Aging-US
- Current challenges and emerging opportunities of CAR-T cell therapies
- (2019) Teresa R. Abreu et al. JOURNAL OF CONTROLLED RELEASE
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL
- (2018) John Rossi et al. BLOOD
- A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
- (2018) Jing Wei et al. CELLULAR IMMUNOLOGY
- Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release
- (2018) Christopher Szot et al. JOURNAL OF CLINICAL INVESTIGATION
- The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review
- (2018) Sheng Zhang et al. OncoTargets and Therapy
- Tumor endothelial marker 8 promotes cancer progression and metastasis
- (2018) Anette M. Høye et al. Oncotarget
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
- (2018) Wanghong Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Modulation of PI3K signaling to improve CAR T cell function
- (2018) Wenting Zheng et al. Oncotarget
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
- (2017) Sara Caratelli et al. Frontiers in Immunology
- Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
- (2017) Thomas Karn et al. JAMA Oncology
- Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
- (2017) Spencer Park et al. Scientific Reports
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
- (2016) De-Gang Song et al. Journal of Hematology & Oncology
- Expression of ROR1 has prognostic significance in triple negative breast cancer
- (2016) Hui-Ping Chien et al. VIRCHOWS ARCHIV
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules
- (2015) Min Soo Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
- (2014) Ezzeldin M. Ibrahim et al. BREAST CANCER RESEARCH AND TREATMENT
- NKG2D CARs as Cell Therapy for Cancer
- (2014) Charles L. Sentman et al. CANCER JOURNAL
- MUC1: a multifaceted oncoprotein with a key role in cancer progression
- (2014) Sritama Nath et al. TRENDS IN MOLECULAR MEDICINE
- ANTXR1, a Stem Cell-Enriched Functional Biomarker, Connects Collagen Signaling to Cancer Stem-like Cells and Metastasis in Breast Cancer
- (2013) D. Chen et al. CANCER RESEARCH
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
- (2013) C. Geldres et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
- (2013) E. Lanitis et al. Cancer Immunology Research
- TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types
- (2012) Amit Chaudhary et al. CANCER CELL
- Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection
- (2012) Manfred Lehner et al. PLoS One
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
- (2011) J. Cheng et al. CURRENT CANCER DRUG TARGETS
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma
- (2009) M. Cullen et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now